Cero Therapeutics Holdings, Inc. ((CERO)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Cero Therapeutics Holdings, Inc. is conducting a Phase 1/1b study titled Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia (CertainT-1). The study aims to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory acute myeloid leukemia (AML) or TP53mut disease. This research is significant as it explores a novel treatment approach for a challenging condition.
Intervention/Treatment: The intervention being tested is CER-1236, an autologous chimeric engulfment receptor T-cell therapy. It is designed to treat AML by targeting and eliminating cancer cells. Additional drugs used include Cyclophosphamide and Fludarabine for lymphodepletion, and Mesna as a chemoprotectant.
Study Design: The study is interventional, non-randomized, and follows a parallel model with no masking. It involves multiple ascending dose and dose expansion of CER-1236 as a single-agent treatment, focusing primarily on treatment outcomes.
Study Timeline: The study began on February 14, 2025, with the latest update submitted on June 27, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The progress of this study could significantly impact Cero Therapeutics’ stock performance, as positive results may enhance investor confidence and market positioning. The competitive landscape in AML treatments is evolving, and successful outcomes could position Cero Therapeutics as a leader in innovative cancer therapies.
The study is currently ongoing, with further details available on the ClinicalTrials portal.